Kornimate/medical-research-clean huggingface dataset:
spirulina oral supplement for enhancing host resilience to virus infection

Conditions: Healthy Volunteers

Summary: this randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, immulina tm, on enhancing host resilience to the effects of viral influenza infection in humans.

this randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, immulina tm, on increasing host resilience against the pathogenic effects of influenza virus infection in normal and immune compromised individuals by measuring a biomarker profile designed to reflect immune components associated with antiviral natural killer cell numbers and activity, cytotoxic t cell numbers, vaccine-related flu-specific antibody responses and cytokine profiles associated with host antiviral innate and adaptive immune responses.

Eligibility criteria:
inclusion criteria: * ages 18-59 (study group 1) or ages 65 and above (study group 2) * any chronic illness must be determined (by pi team) to be stable as evidenced by no changes in medical regimens within 30 days of enrollment. * ability to comprehend the specific activities required to participate in the trial for which the participant is to be enrolled. exclusion criteria: * any acute illness or significant injury within 30 days of enrollment. * specific disease entities, which, in the opinion of the pi, could reasonably be assumed to have dysfunctional immune function as a component of their illness. these include hiv, aids, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, type-1 diabetes mellitus, guillain-barr syndrome, grave's disease, hashimoto's thyroiditis, myasthenia gravis or vasculitis. * active autoimmune diseases regardless of clinical stability. a history of autoimmune disease that is not considered active (i.e. no medical therapy for at least 1 year prior to enrollment) will not be excluded. * history of unstable chronic illness within 30 days of enrollment. * unable/unwilling to commit to multiple research clinic visits which will be described in detail.

Keywords: immulina tm natural killer cells (nk) botanical dietary supplement influenza dietary supplementation
screening for endometrial abnormalities in overweight and obese women

Conditions: Endometrial Cancer

Summary: the purpose of this study is to develop an endometrial biopsy screening program for endometrial cancer and its precursor lesions in overweight and obese women. there is a bmi threshold at and above which optimal screening parameters exist for identifying endometrial cancer and its precursor lesions in overweight and/or obese women. prevention, diagnosis and treatment of endometrial cancer and its precursor lesions in overweight and/or obese women offers substantial health benefits.


Eligibility criteria:
inclusion criteria: * have bmi ≥25. * be patients of the st. luke's and roosevelt gynecology clinics and faculty practices or be receiving bariatric surgery. * complete a full medical history, a detailed menstrual and/or postmenopausal bleeding history, and endometrial biopsy. * have a negative pregnancy test, if of childbearing age. * be at least 18 years of age. * have signed a written informed consent document. * be willing and able to comply with the study requirements. exclusion criteria: * have a bmi \<25. * have a prior hysterectomy. * be pregnant or have a positive pregnancy test * have untreated vaginal, cervical, or adnexal infection. * recent treatment of std
transverse versus longitudinal groin incision in vascular surgery

Conditions: Peripheral Arterial Disease(PAD); Aneurysmal Disease

Summary: the purpose of the study is to examine whether incision type has an influence on the development of groin wound complications after operation in the groin in vascular surgery. the main questions it aims to answer are: does a transverse incision in the groin lead to fewer surgical site complications than a longitudinal incision? does a transverse incision lead to fewer readmissions, fewer reoperations, shorter length of hospital stay, and a lower amputation rate. participants will undergo vascular surgery in the groin with either a transverse or longitudinal incision. the incision type will be selected randomly.


Eligibility criteria:
inclusion criteria: • patients undergoing vascular reconstruction with a groin incision exclusion criteria: * patients previously operated with a groin incision. * patients undergoing operation due to trauma, bleeding, or pseudoaneurysm. * patients operated within the first 24 hours of admission. * if it prior to the operation is deemed necessary with a muscleplasty.

Keywords: groin wound complications surgical site complications surgical site complication vascular surgery incision type incision
short-term effects of perindopril-amlodipine versus perindopril-indapamide in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Hypertension

Summary: this was a double-blinded randomized controlled trial of 24-hour blood pressure control in sub saharan type 2 diabetes patients, newly diagnosed for hypertension. they were allocated to receive either a fixed combination of perindopril + amlodipine or perindopril + indapamide for 42 days.

this was a double-blinded randomized controlled trial conducted at the national obesity center and the cardiology unit of the yaoundé central hospital in cameroon from october 2016 to may 2017. eligible patients were type 2 diabetes patients, newly diagnosed for hypertension (grade i or ii) with confirmation on ambulatory bp monitoring (abpm). patients were either on lifestyle modification alone or on a stable anti-diabetic treatment for the past three months, aged 25-65 years naïve to any anti-hypertensive treatment, who provided their written informed consent. participants were assigned to receive as anti-hypertensive treatment perindopril-amlodipine once daily or perindopril-indapamide at the same frequency. the two groups were followed up and monitored for sixth weeks and patients did not take any additional treatment with bp modifying properties. the primary outcome was the relative change in circadian blood pressure profile between the two groups after six weeks of treatment

Eligibility criteria:
inclusion criteria: * adult diabetes patients aged between 25-65 years, * with grade i or grade ii (who classification) hypertension on the clinical measure, confirmed by abpm * naïve to any anti-hypertensive treatment * written informed consent. exclusion criteria: * patients with grade iii hypertension (who classification) were classified as hypertensive emergency, * estimated creatinine clearance ˂30ml/min/1.73m2 (using modified diet in renal diseases formula) * alanine transaminase (alt)≥ 3 normal * any contraindication to study drugs (hypersensitivity) * pregnant or breastfeeding women

Keywords: diabetes hypertension blacks africa ace inhibitor calcium channel blocker diuretic
long-term results of percutaneous left atrial closure at brest university hospital (clapot)

Conditions: Atrial Fibrillation; Cardioembolic Stroke; Left Atrial Appendage Thrombosis; Anticoagulant-induced Bleeding

Summary: atrial fibrillation represents an important risk of cardioembolic stroke. in more than 90% of cases, thrombus originate in the left atrial appendage. therefore guidelines recommend the anticoagulation of patients with atrial fibrillation and a significant cardioembolic risk, predicted by the cha2ds2vasc score. however, serious bleeding complications may definitively contraindicate the use of anticoagulants. for those patients, percutaneous left atrial appendage occlusion (laao) has became a recommended alternative to prevent the thrombus formation and reduce the risk of cardioembolic events. in the chu of brest, more than 120 patients have been treated with laao for the last 8 years with two different occluder devices : watchman®, boston scientifc and amplatzer amulet®, abbott laboratories. this retrospective longitudinal observational study named clapot (chu of brest' left atrial appendage percutaneous occlusion treatment) aims to evaluate the long term results of this procedure for effectiveness and safety and to compare the results between the two devices (watchman and amplatzer).


Eligibility criteria:
inclusion criteria: * major * non opposition * all patients with non-valvular atrial fibrillation and a definitive contraindication to anticoagulants who underwent left atrial appendage occlusion in the chu of brest between december 2014 and august 2023 exclusion criteria: * minor * patients under tutorship or curatorship * formulated opposition

Keywords: left atrial appendage occlusion · watchman · amplatzer amulet · atrial fbrillation · stroke · echocardiography · cardiac computed tomography angiography
oropharyngeal administration of colostrum to very low birth weight infants

Conditions: Infant, Very Low Birth Weight

Summary: the purpose of this study is to explore the effects of oropharyngeal administration of colostrum to very low birth weight infants on siga and lactoferrin, in order to explore the protect immune function of colostrum to very low birth weight infants, to improve the utilization of breast milk and reduce infection rates of very low birth weight infants.

the number of very low born weight infants increased every year.they are suffer from many questions.recent studies have shown that oropharyngeal administration of colostrum to very low birth weight infants can reduce the time reach full enteral nutrition .but there are no evidence support that it can promote infants' immune response. the hypothesis of the current study is that oropharyngeal administration of colostrum to very low birth weight infants may increase the secretion of siga in urine and saliva. the current study adopts randomized, double blind, controlled intervention trial, gives oropharyngeal administration of colostrums to very low birth weight infants in intervention group and oropharyngeal administration of normal saline to control group. all indicators in this study are discrete traits, for siga、lactoferrin number in saliva and urine， number of crp，time begin oral feeding，time up to full enteral feeding， person's chi-square tests were used for comparisons. for blood culture results，the number of necrotizing enterocolitis (nec) occurred， the investigators use chi-square tests for comparisons between two groups. the study expects that oropharyngeal administration of colostrum to very low birth weight infants can increase the secretion of siga in urine and saliva.

Eligibility criteria:
inclusion criteria: 1. born weight≤1500g 2. transferred to our hospital within 24 hours after birth 3. the mother can provide colostrum 4. parents of the infants agreed to participate in this study exclusion criteria: 1. the infants suffering from life-threatening conditions ,such as severe heart disease,whose survival time are expected \<30d 2. the infants suffering from any kinds of disease,which impact they take human milk by mouth.(such as gastrointestinal malformations, nec, etc.） 3. human milk is contraindicated * an infant whose mother : * is infected with the human immunodeficiency virus (hiv) * is taking antiretroviral medications * has untreated active tuberculosis * is infected with human t-cell lymphotropic virus type l or ll * is using or dependent on an illicit drug except if the breastmilk is medically indicated * is taking prescribed cancer chemotherapy agents contraindicated for breastfeeding * is receiving any medications contraindicated in breast feeding * is receiving diagnostic or therapeutic radioactive isotopes or exposure to radioactive materials (for as long as they are radioactive in the milk) * an infant diagnosed with galactosemia, a rare genetic metabolic disorder

Keywords: oropharyngeal breastmilk colostrum human milk premature infant
use of various configurations of different arterial grafts in total arterial revascularization

Conditions: Coronary Syndrome; Coronary Disease; Coronary Artery Disease

Summary: cabg is a difficult and very critical surgery , it is done to revascularize the myocardium in cases of cardiac ischemia . if the myocardium is still viable in selected patients then it is the treatment of choice with outstanding results . indications of this operation are more than 50% diameter stenosis of the left main coronary artery, more than 70% diameter stenosis in proximal left anterior descending artery (lad), more than 70% diameter stenosis in three major coronary vessels, ventricular septal defect related to myocardial infarction , papillary muscle rupture , free wall rupture , ventricular pseudoaneurysm , life-threatening ventricular arrhythmias, and cardiogenic shock. multiple methods have evolved to achieve the best outcome .the revascularization process depend on two main graft either artery or venous , each has its advantage and disadvantage according to their elasticity , ability to deliver an adequate flow and sustain high blood pressure. our focus is on the different configuration used for the revascularization by using the artery grafts only due to the superiority of the artery graft in comparison to the venous according to the outcomes and not the feasibility of the technique .it is recommended to begin with internal thoracic artery then saphenous vein if both failed then multiple conduits will be used . bilateral internal thoracic artery grafting can be an optimal option for coronary artery bypass grafting ,but it's the long-term outcome is still under study.there is no accepted configuration of the anastomosis to be used in the multiple conduits .


Eligibility criteria:
inclusion criteria: * all patients with multi-coronary vessel disease eligible for cabg surgery . exclusion criteria: * 1. age more than 70 years 2. diabetic patient 3. single vessel disease 4. associated valvular disease 5. previous open heart surgery 6. hemodynamic unstability 7. ejection fraction less than (40%)
helping patients with spinal stenosis make a treatment decision: a randomized study assessing the benefits of health coaching

Conditions: Spinal Stenosis

Summary: treatment options for lumbar spinal stenosis include surgical and non-surgical approaches. for most people, the decision depends on how bothered they are by their symptoms and how they feel about having surgery. since individuals with the same clinical presentation may feel differently about their symptoms and how they view the benefits and harms of their options, there is no agreed upon "best"treatment. it has been shown that, for "preference-sensitive" decisions like this one, decision aids (tools that pair balanced, evidence-based information regarding treatment options with values clarification) improve patients'knowledge and realistic expectations, lower decisional conflict, increase patient involvement in decision making, decrease the number of undecided, and increase agreement between values and choice.1 the spine center, in collaboration with the center for shared decision making (csdm) at dartmouth hitchcock medical center (dhmc), has been providing patients with decision aids (das) for several years. hypothesis: patients identified as having low literacy and/or high decisional conflict after viewing a video decision aid will show greater resolution of their decisional conflict, higher decision self-efficacy and less decision regret if a coaching intervention is paired with a video decision aid. decision support in the form of coaching develops patients'skills in preparing for a consultation and deliberating about their options.2 a study of women with abnormal uterine bleeding showed that pairing coaching with a da helped patients clarify their values and preferences, reduced costs, and increased long term satisfaction.3 the investigators plan to assess the impact of coaching in patients with lumbar spinal stenosis who are referred to the csdm for a video decision aid about their treatment options. the investigators are also interested to learn whether screening for low literacy and high decisional conflict can identify a subgroup of patients who are more likely to benefit from coaching.


Eligibility criteria:
inclusion criteria: * english speaking * adults over 18 exclusion criteria: * non-english speaking * anyone under the age of 18 * prisoners

Keywords: decisional conflict coaching decisional regret
polaprezinc treatment for enzalutamide- or abiraterone-resistant crpc

Conditions: Castration-resistant Prostate Cancer

Summary: the purpose of this study is to evaluate clinical safety and efficacy of a gastric ulcer drug, polaprezinc (pol), with the ar-inhibitor abiraterone in chinese patients with castration-resistant prostate cancer (crpc).

prostate cancer (pca) is a major disease that affects 14.1% male population worldwide with a 6.8% mortality rate in 2020 (https://gco.iarc.fr/). in china, the pca incidence rate is lower than in europe and the us but increases rapidly. androgen deprivation therapy (adt) has been the most used treatment for men with advanced prostate cancer for decades. despite the initial favorable response, nearly all patients progress to castration-resistant prostate cancer (crpc) and subsequently succumb to the disease within 1-3 years. zinc-l-carnosine (znc), also called polaprezinc (otherwise known as pepzin gi™), is a chelated compound that contains l-carnosine and zinc. some reports indicated that pol is effective in restoring the gastric lining, healing other parts of the gastrointestinal (gi) tract, improving taste disorders, improving gi disorders, and enhancing skin and liver. the primary mechanisms of pol action are identified as anti-inflammatory and antioxidant pathways. we have identified prdx5 as a therapeutic target and repurposed polaprezinc (pol) as its inhibitor for the treatment of crpc. crpc patients will be enrolled with their fully informed consent. patients will be on abiraterone/prednisone, abiraterone/prednisone plus polaprezinc granules, or with other treatments according to patients' wishes in consultation with physicians. polaprezinc will be 75 mg b.i.d., for 6 months. a standard regimen will be used for other treatments. psa will be measured every month. ect will be taken before and after treatment.

Eligibility criteria:
inclusion criteria: 1. male patients were older than 18 years of age. 2. patients with measurable disease were required to have documented disease progression by response evaluation criteria in solid tumors (recist) (28) with at least one bone metastatic lesion. patients with non-measurable disease were required to have at least two consecutive increases (relative to a reference value measured at least a week apart) in serum psa. 3. patients had been taking abiraterone or enzalutamide for at least three consecutive months and showed a persistent rise in psa. 4. life expectancy \>6 months exclusion criteria: 1. patients had taken polaprezinc previously. 2. patients had cancer therapy (other than adt) within 4 weeks before enrolment. 3. patients had malignancies other than prostate cancer. 4. patients had uncontrolled severe illness or medical conditions.

Keywords: crpc; pol
apathy in tourette syndrome and changes in quality of life

Conditions: Tourette Syndrome; Apathy

Summary: tourette syndrome is a complex neuropsychological disorder with both motor and vocal tics associated with multiple psychological co-morbidities. apathy has not been widely studied in patients with tourette syndrome. apathy can result in decrease in self-care and disease control. in this study investigators will compare the occurrence of apathy in the adolescent tourette syndrome population (at the uf center for movement disorders and neurorestoration) to an age and gender matched control population. investigators will also assess the role of commonly used medications in the tourette population (neuroleptics and selective serotonin receptor inhibitors) in the occurrence of apathy.

tourette syndrome(ts) is a complex neuropsychological disorder with both motor and vocal tics associated with multiple psychological co-morbidities. the most common co-morbidities include obsessive compulsive disorder (ocd), attention deficit and hyperactivity disorder (adhd) and depression. apathy has not been extensively studied in the tourette syndrome population. apathy is currently defined as reduced motivation, with symptoms in at least two of three domains of reduced initiative, reduced interest and/or reduced emotional responsiveness. a study assessed the prevalence of apathy in multiple movement disorders and reported that apathy is much more common in disorders associated with slowed movements like parkinson disease while less common in disorders with increased movements like huntington disease and tourette syndrome in adults. however, no apathy studies in adolescent patients with tourette syndrome are published. disengagement from treatment may affect health outcomes in other disease states. apathy has significant effects on the quality of life and health outcomes in many patients. apathy can be a direct manifestation of the neuropsychological process (intrinsic to the disease) or can be secondary to medication side effects most notably anti-dopaminergic agents and some reports of selective serotonin receptor inhibitors (ssri). further attention to the prevalence and impact of apathy in the adolescent tourette syndrome population is needed to explore if this may be a factor influencing ts management and ultimately quality of life (qol). multiple psychotropic medications are used in the management of tics as well as the psychological co-morbidities. how these medications affect apathy prevalence in tourette syndrome patients is not known.

Eligibility criteria:
inclusion criteria: * diagnosis: tourette syndrome * age: 12-16 years * followed at the cmdnr exclusion criteria: * history of cerebral palsy or traumatic brain injury
efficacy of dihydroartemisinin for treating acne vulgaris

Conditions: Acne Vulgaris

Summary: the goal of this clinical trial is to learn if dihydroartemisinin (dha) works to treat acne vulgaris in adults. the main question it aims to answer is: • does dha improve the acne severity by at least one grade after treatment. researchers will treat patients who are clinically diagnosed as acne vulgaris to see if dha works to alleviate the symptoms of acne vulgaris. participants will: * take dha every day for 3 months * visit the clinic once every month for checkups and tests


Eligibility criteria:
inclusion criteria: * clinically diagnosed with acne vulgaris; * for female patients, no pregnancy plans within the next 6 months. exclusion criteria: * patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months; * patients who have used topical medications for acne within the past 2 weeks; * pregnant or breastfeeding women; * patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Keywords: acne vulgaris dihydroartemisinin